Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Mastering the Medical Affairs Professional Role: Inside and Out
Summary
In this episode, Tom Caravela welcomes Kent Christofferson to discuss his career journey and insights into the MSL role. Kent shares his transition from academia to industry, highlighting the importance of mastering the MSL role and thinking like a Key Opinion Leader (KOL). He delves into the value proposition of MSLs, the significance of team effectiveness, and the challenges of handling multiple roles. The conversation covers compliance, technology, and future medical affairs directions, emphasizing digital engagement and the shift towards relationship-based interactions. Kent concludes with strategies for effective KOL engagement and the importance of leadership support in the evolving MSL landscape.
Kent Christopherson, Senior Director, Medical Affairs at Orchard Therapeutics discusses the art of Mastering the Medical Affairs Professional Role Internally and Externally.
Kent shares…
👉 Why MSLs need to “think like a KOL”
👉 The importance of Individual Development Plans
👉 Integrated Team Effectiveness Model- (ITEM) ref: 2006, Louise Lemieux-Charles, Wendy L McGuire
👉 Why clinical insights is the currency for MSL value internally
👉 Why it is vital to understand what KOLs motivation is in order to ensure value and meet deliverables
Medical Science Liaison, Key Opinion Leader, MSL Career Transition, Medical Affairs Strategies, Effective KOL Engagement
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO